The Future Vaccine Manufacturing Research Hub (Vax-Hub)

Lead Research Organisation: University College London
Department Name: Biochemical Engineering

Abstract

Vaccines are the most successful public health initiative of the 20th century. They save millions of lives annually, add billions to the global economy and extended life expectancy by an average of 30 years. Even so, the UN estimates that globally 6 million children each year die before their 5th birthday. While vaccines do exist to prevent these deaths, it is limitations in manufacturing capacity, technology, costs and logistics that prevent us for reaching the most vulnerable. The UK is a world leader in vaccine research and has played a significant leadership role in several public health emergencies, most notably the Swine Flu pandemic in 2009 and the recent Ebola outbreak in West Africa. While major investment has been made into early vaccine discovery - this has not been matched in the manufacturing sciences or capacity. Consequently, leading UK scientists are forced to turn overseas to commercialise their products.

Therefore, this investment into The Future Vaccine Manufacturing Hub will enable our vision to make the UK the global centre for vaccine discovery, development and manufacture. We will create a vaccine manufacturing hub that brings together a world-class multidisciplinary team with decades of cumulative experience in all aspects of vaccine design and manufacturing research. This Hub will bring academia, industry and policy makers together to propose radical change in vaccine development and manufacturing technologies, such that the outputs are suitable for Low and Middle Income Countries.
The vaccine manufacturing challenges faced by the industry are to (i) decrease time to market, (ii) guarantee long lasting supply - especially of older, legacy vaccine, (iii) reduce the risk of failure in moving between different vaccine types, scales of manufacture and locations, (iv) mitigating costs and (v) responding to threats and future epidemics or pandemics. This work is further complicated as there is no generic vaccine type or manufacturing approach suitable for all diseases and scenarios. Therefore this manufacturing Hub will research generic tools and technologies that are widely applicable to a range of existing and future vaccines.
The work will focus on two main research themes (A) Tools and Technologies to de-risk scale-up and enable rapid response, and (B) Economic and Operational Tools for uninterrupted, low cost supply of vaccines. The first research theme seeks to create devices that can predict if a vaccine can be scaled-up for commercial manufacture before committing resources for development. It will include funds to study highly efficient purification systems, to drive costs down and use genetic tools to increase vaccine titres. Work in novel thermo-stable formulations will minimise vaccine wastage and ensure that vaccines survive the distribution chain. The second research theme will aim to demystify the economics of vaccine development and distribution and allow the identification of critical cost bottlenecks to drive research priorities. It will also assess the impact of the advances made in the first research theme to ensure that the final cost of the vaccine is suitable for the developing world.

The Hub will be a boon for the UK, as this research into generic tools and technologies will be applicable for medical products intended for the UK and ensure that prices remain accessible for the NHS. It will establish the UK as the international centre for end-to-end vaccine research and manufacture. Additionally, vaccines should be considered a national security priority, as diseases do not respect international boundaries, thus this work into capacity building and rapid response is a significant advantage.

The impact of this Hub will be felt internationally, as the UK reaffirms its leadership in Global Health and works to ensure that the outputs of this Hub reach the most vulnerable, especially children.

Planned Impact

To become an International Centre of Excellence the Hub will interact with multiple stakeholders in the vaccine community and ensures that the benefits of this research are felt far and wide. The immediate beneficiaries of this work will be the organisations who engage with the Hub, including UK industry and academia, Catapults, such as the National Biologics Manufacturing Centre and LMIC vaccine manufacturers. The outputs from this work will also assist other manufacturing Hubs and further the work of the UK Vaccine Network, as many of the research topics tie into strategic policy areas. This work will create new and improved vaccines for LMICs, enable our ability to respond to epidemic scenarios and ultimately boost the UK bio-economy by advancing vaccine manufacturing.

The mechanism of engagement will be through training and online courses, conferences and publications in peer-reviewed journals, feasibility projects that feed projects into the Catapults centres, and Expert Interaction Vouchers. These will be promoted through existing networks such as KTN, academic networks, other Hubs and the Developing Country Vaccine Manufacturing Network (DCVMN).

Training and Online Courses. The Hub members currently run training programmes in bioprocessing, analytics and vaccine development as part of its CPD offering to the vaccine industry and research outputs from the Hub will be included into these training programmes. We will offer funding for 10 places annually for academics and industry from LMICs to attend these courses. To address the national shortage of Qualified Persons (QPs), we will recruit two trainee QPs and provide them with hands-on training in user GMP manufacturing facility, and mentorship to allow them to complete their training and support industry needs. A dedicated Training officer will ensure maximum dissemination of the Hub's work, especially to the DCVMN, by creating online training material that will survive beyond the grant period.
Conferences and Publications. The Hub will hold an all user annual meeting where outputs from the Grand Challenges and Feasibility projects are presented. All partners will be encouraged to publish in Open Access journals. Business Briefings, Special Interest Groups and Industry Open Days, will ensure we continue to increase user engagement over the lifetime of the Hub and create the trained individuals with skills to take the industry forward.
Feasibility Projects will benefit all users that are not currently part of the Hub. Each project can range from a minimum of 6 months to 3 years and receive funding of up to a maximum of £100k p.a. for personnel, PI time and consumables. These grants will explore early technologies and help to generate pilot data for follow on funding. It will link to Catapults, such as the National Biologics Manufacturing Centre, to test feasibility.
Expert Interaction Vouchers will be available for UK and LMIC vaccine manufacturers. Vouchers (up to £35k per voucher) can cover the cost of travel, subsistence and consultancy. It can also be used to fund a maximum 6-month secondment to a facility or research group to build expertise.

LMICs are beneficiaries of this work, which will improve the supply capacity and cost base of existing vaccines and introduce new vaccine technologies to these groups. The vaccine candidates researched by the Hub are on pathogens that primarily affect low-income countries listed on the DAC list, such as malaria, Rift Valley fever, Dengue, pneumococcal disease and TB. Other DAC listed countries will benefit from Hub activities, as we will interact through the DCVMN to offer training, consultancy and secondments through interaction vouchers and feasibility projects.

Organisations

 
Description The Vax-Hub has now established a robust internal and external management structure and staff are progressing with their research outcomes, working on the three technologies. Significant achievements have been obtained for each:
Technology 1: Establishment of a single-use adenovirus manufacturing platform, this has now made GMP compliant and is being used towards manufacture of a vaccine against COVID-19.
Technology 2: Virus-like Particle vaccines production process for Dengue fever, Foot-and-Mouth Disease, Malaria.
Technology 3: Conjugate vaccines - novel strains have been produced and tested, automated microscale methods developed for rapid process development

A reliable and robust process for Platform Funding has been established, two calls for £10K interaction vouchers and one call for £100K Feasibility Studies have been completed and projects awarded and announced. Training objectives have also been completed, with more than 30 places assigned to LMIC manufacturers employees for courses run worldwide.

Since January 2020 the Oxford Vax-Hub team of researchers and PIs have been working steadily, in collaboration with other scientists in Oxford, on a Covid-19 vaccine. This is based on the adenovirus vector platform. The team has been working to optimise the platform according to the original Vax-Hub deliverables, resulting in a much quicker achievement of these objectives. The Vax-Hub concept and provision has been instrumental in getting the Oxford COVID vaccine project off the ground. Without it, we wouldn't have been ready to go on the manufacturing scale up or have the staff to do the work needed.
Exploitation Route The new technologies and methods developed by the Vax-Hub will be crucial in ensuring vaccine supply at reduced cost:
Technology 1: Establishment of a single-use GMP compliant adenovirus manufacturing platform, this is a flexible platform able to work with multiple serotypes which is easily transferable to LMIC manufacturers with limited capabilities. This technology has been now significantly developed with associated government funding during the pandemic and a covid-19 vaccine is now available worldwide, manufactured and distributed by AstraZeneca.
Technology 2: Virus-like Particle vaccines production process for Dengue fever, Foot-and-Mouth Disease, Malaria. Findings from these projects is in collaboration with companies and aims at translating some of the novel constructs and engineering methodologies to them before end of the grant
Technology 3: Conjugate vaccines - the methods being established aim at a new strain and method capable of producing Pneumococcal vaccine doses at reduced cost.
Sectors Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology

 
Description Since January 2020 the Oxford Vax-Hub team of researchers and PIs have been working steadily, in collaboration with other scientists in Oxford, on a Covid-19 vaccine. This is based on the adenovirus vector platform. The team has been working to optimise the platform according to the original Vax-Hub deliverables, resulting in a much quicker achievement of these objectives. The team has achieved significant results manufacturing an efficacious vaccine against covid-19, which is now being manufactured and distributed worldwide by AstraZeneca.
First Year Of Impact 2020
Sector Healthcare,Manufacturing, including Industrial Biotechology
Impact Types Societal,Policy & public services

 
Description A policy engagement training workshop is being organised targeted at post-doctoral researchers which will provide an overview of the policy-making process including how and when to most effectively engage with policy-makers in order to feed into the policy-making cycle and will enable PDRAs to consider Vax Hub research in light of current vaccine policy challenges in a co-design session with policy makers.
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Contribution by Professor Daniel Bracewell; Professor Paul Dalby, Professor Martina Micheletti, Dr Stephen Morris to UCL's institutional response to Parliamentary Science and Technology Select Committee (Commons) inquiry - Coronavirus: Lessons learnt
Geographic Reach National 
Policy Influence Type Gave evidence to a government review
URL https://committees.parliament.uk/writtenevidence/14934/pdf/
 
Description Contribution to a report by the DELVE Initiative on key issues involved in developing, evaluating, manufacturing and distributing a vaccine for COVID-19, the impact of those challenges and future strategies to mitigate their effects.
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
URL https://rs-delve.github.io/reports/2020/10/01/covid19-vaccination-report.html
 
Description House of Commons Select Committee
Geographic Reach Multiple continents/international 
Policy Influence Type Gave evidence to a government review
 
Description Research evidence on vaccine manufacturing used by Parliamentary Office for Science and Technology
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact Rapid response content is published within weeks to brief Parliamentarians on important research developments.
URL https://post.parliament.uk/manufacturing-covid-19-vaccines/
 
Description COV19 OxfordVacc-01
Amount £31,179,621 (GBP)
Funding ID COV19 OxfordVacc-01 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2020 
End 03/2022
 
Description International Veterinary Vaccinology Network
Amount £80,460 (GBP)
Funding ID MC_PC_17219 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2018 
End 04/2019
 
Description Investment in Policy to maximise the potential of biomanufacturing in the post-COVID-19 world
Amount £150,000 (GBP)
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 04/2021 
End 12/2022
 
Description Manufacturing characterization and costing of vaccine technologies (MCCVax)
Amount $1,372,422 (USD)
Funding ID OPP1154682 
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 12/2019 
End 12/2021
 
Description Marie Sklodowska-Curie Individual Fellowships
Amount € 224,934 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 07/2019 
End 06/2021
 
Description Meeting the UK demand for COVID19/SARS-CoV-2 vaccines via integrated manufacturing and supply chain optimisationUKRI
Amount £448,148 (GBP)
Funding ID EP/V01479X/1 
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 07/2020 
End 01/2022
 
Description Rapid development of manufacturing processes for future production of adenovirus-vectored COVID19 vaccine at million-dose scale
Amount £411,388 (GBP)
Funding ID MC_PC_19058 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2020 
End 09/2020
 
Description The development of yeast strains to produce SARS-CoV-2 antigens for serological assays enabling the detection of COVID-19 cases in the UK population
Amount £48,854 (GBP)
Funding ID 61380 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 05/2020 
End 01/2021
 
Description USD studies on the ChAdOx1 platform manufacturing process
Amount £235,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 01/2021 
End 01/2022
 
Description Unravelling the molecular mechanisms of invasive pneumococcal disease
Amount £1,900,000 (GBP)
Funding ID 221803/Z/20/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2021 
End 01/2026
 
Description nCoV: Rapid Clinical Development of ChAdOx1 nCoV-19
Amount £2,174,847 (GBP)
Funding ID MC_PC_19055 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2020 
End 09/2021
 
Title Fully integrated automated screening platform 
Description Automation of preculture, cell culture, harvest and periplasmic extraction has all been achieved in one seamless protocol without the need of user interaction from the start to finish. Measurements of cell growth is included and through integrating the robotic platform with MatLab it has been possible to integrate all outputs created within the process to inputs required; for example preculture optical density (extent of growth) is measured and inoculation volumes are calculated using this value. This integration with Matlab and for the whole platform to be handsfree is novel to the institution and a useful tool which can be applied to other projects. This will be published and presented in upcoming events 
Type Of Material Improvements to research infrastructure 
Year Produced 2020 
Provided To Others? No  
Impact This screening tool can be used on any number of cell culture projects and adapted as needed for different protocols. The integration is novel and can be used to instruct other users within and outside the institution. 
 
Title Generation of PGCT strains for the production of candidate glycoconjugate vaccines against pneumococcus serotype 4 
Description Purposely modified E. coli strains transformed with 3 plasmids PGCT system to produce candidate glycoconjugate vaccines against pneumococcus serotype 4. 
Type Of Material Biological samples 
Year Produced 2020 
Provided To Others? No  
Impact A series of tools were generated to improve the quality of candidate pneumococcal vaccines produced from bacterial cells. 
 
Title Modeling and optimisation of vaccine supply chains 
Description The focus is on is developing a vaccine supply-chain model that can simulate the flow of vaccine doses from manufacturing plants to service delivery points where vaccines are administered to targeted patients. The model may be used to optimise supply chain operations, ensuring uninterrupted supply of vaccines at minimum cost per dose delivered. The long-term objective is to integrate such supply-chain models with vaccine manufacturing process models in order to capture the interplay between vaccine manufacturing and supply-chain performance. 
Type Of Material Computer model/algorithm 
Year Produced 2020 
Provided To Others? No  
Impact We are developing a case study in a LMIC (Tanzania). The data were collected from websites and contacts with various organisations, including WHO, GAVI, UNICEF and PATH, as well as local governments. The developed vaccine supply chain model is capable of simulating the flow of vaccines from central vaccine store to district vaccine stores (four echelon model). 
 
Title Techno-economic modeling of conjugate vaccine production 
Description The focus is on a conjugate vaccine for pneumonia. Currently used chemical conjugation technology makes this vaccine expensive and a bioconjugation technique is under development by colleagues within the Vax Hub (GC1.1.2). Our research aims at comparing the production processes of pneumonia vaccines using both chemical and biological conjugation in term of techno-economics. 
Type Of Material Computer model/algorithm 
Year Produced 2020 
Provided To Others? No  
Impact We have developed semi-empirical models of the upstream production processes (bioreactors) as well as data-driven models for the downstream separation and purification processes. These models will feed into the commercial simulator SuperPro Designer. Future steps will entail using this platform for identifying hot spots in the production process, optimizing some of the operating conditions and the production schedules, and conducting a techno-economic comparison between chemically and biologically conjugated vaccines. In the long run, these process modeling capability will be integrated with vaccine supply chain modeling to optimize the whole vaccine value chain. 
 
Description Applikon Biotechnology Vax-Hub Partner 
Organisation Applikon Biotechnology B.V.
Country Netherlands 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2021
 
Description Assuring the quality of dengue vaccine in a VLP form 
Organisation National Institute for Biological Standards and Control (NIBSC)
Country United Kingdom 
Sector Public 
PI Contribution In order to assure the quality of dengue vaccine, in a VLP form, a set of robust analytics will be developed. Those analytics methods will allow the characterization and quality evaluation at small scale. There is a lack of robustness in commercially available reference materials/Antibodies; collaboration with an organisation such as NIBSC, who will be working either directly or indirectly with dengue or dengue based materials in various forms, will allow the best commercially available materials to be identified.
Collaborator Contribution NIBSC will provide scientific advice as well as biological materials which will have a major impact on the development of the analytics for the biochemical and immunochemical characterization of the dengue vaccine.
Impact The outputs/outcomes that are aimed to be achieved with this collaboration will have a direct impact on the development of robust analytics for product characterization and quality evaluation,at small scale, as far as the biochemical and immunchemical properties are concerned.
Start Year 2020
 
Description AstraZeneca Vax-Hub Partner 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Access to QA / Analytical equipment, valued at £20,000 per year Attendance and input at project meetings/ Upstream or down-stream bioprocesses / Analytics / HT /spokes / Supervision of feasibility studies/interaction vouchers, values at £10,000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2021
 
Description CPI Darlington Vax-Hub Partner 
Organisation Centre for Process Innovation (CPI)
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Access to manufacturing equipment for validating scale down studies, new and novel technologies and relevant analytical equipment/ Access to QA / Planning data / Database for network building / Analytical equipment / Manufacturing platforms, valued @£30,000per year Attendance and input at project meetings/ Provision of expert input on supply chain / Upstream or downstream bioprocesses / Manufacturing / Formulation / Drug delivery / Analytics / HT/ Assistance with identification of new user companies/spokes / Supervision of feasibility studies/interaction vouchers, valued @£15,000per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description Establishing the use of microscale chromatography-for downstream process optimization of Group B streptococcus polysaccharides 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution UCL Biochemical Engineering has extensive experience in using scale-down technologies for the rapid definition of protein purification protocols. This will be applied to development and optimization of assays and protocols for use in manufacture of conjugate vaccines. Particular emphasis will be placed on the development of High-throughput analytics based on lectin binding for detection of polysaccharide which are compatible with scale-down purification technologies Once developed at UCL the procedures and assays will be transferred to Hilleman Labs for routine use in process development for this and other vaccines
Collaborator Contribution Hilleman Labs is developing a polysaccharide conjugate vaccine against Group-B Streptococcus (GBS). They will provide access to current materials and methodologies for process development. Hilleman labs have provided material for assay development. Assays and protocols developed at UCL will be transferred to Hilleman Labs for routine use in development of future vaccines in a LMIC environment.
Impact Successful VaxHub Interaction voucher application for 6 month pilot project. Value £10,000 Poster abstract submitted for presentation at the ECI Vaccine Technology VIII conference, June 14 -19 2020. Title: Design of a lectin based bacterial polysaccharide assay for high throughput process development of conjugate vaccine products. Due to COVID-19 restrictions this conference has been postponed (new date not yet confirmed).
Start Year 2019
 
Description Exploiting genetic diversity of Saccharomyces cerevisiae for VLP production 
Organisation Phenotypeca
Country United Kingdom 
Sector Private 
PI Contribution Expertise in the design and development of novel VLP vaccines to investigate the feasibility of the S. cerevisiae expression platform.
Collaborator Contribution Expertise in the use of yeast strains (Saccharomyces) and high-throughput screening for the expression of therapeutic proteins.
Impact Successful application to interaction voucher from Vax-Hub to progress proof of concept studies. As a result of collaboration with the Jenner, Innovate UK Rapid response to COVID-19 competition awarded to Phenotypeca (See Further Funding section - "Innovate UK: 61380 - The development of yeast strains to produce SARS-CoV-2 antigens for serological assays enabling the detection of COVID-19 cases in the UK population"). Successful award of funding for Feasibility Study (See Collaborations and Partnerships - "Improving VLP vaccine production from baker's yeast").
Start Year 2020
 
Description Exploring the potential of solid dose vaccines 
Organisation Enesi Pharma
Country United Kingdom 
Sector Private 
PI Contribution Development of a supply-chain optimisation model including solid dose vaccines in comparison to traditional vaccine doses.
Collaborator Contribution Providing Vax Hub with some technical details about the solid dose properties, including stability.
Impact No impact yet. Disciplines involved: operational research; process systems engineering; vaccine manufacturing
Start Year 2019
 
Description Hilleman Labs 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Hilleman Labs Vax-Hub Partner 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, including valuable LMIC perspective.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description Improving VLP Vaccine Production from Baker's Yeast 
Organisation Phenotypeca
Country United Kingdom 
Sector Private 
PI Contribution Phenotypeca and the University of Oxford's Jenner Institute are collaborating on a feasibility study to improve the production of virus-like particle (VLP) vaccines from baker's yeast, Saccharomyces cerevisiae, for sustainable manufacturing in low- and middle-income countries (LMICs). The candidate VLP selection (hepatitis B, human papillomavirus, and AP205 phage) and construct designs were performed in close collaboration with Aadil El-Turabi in Sarah Gilbert's research group at Oxford's Jenner Institute. They represent a variety of VLP types with potential for different applications. Characterisation (biochemical, biophysical, antigenic properties) of resultant VLP products from diverse hosts will be assessed.
Collaborator Contribution Phenotypeca's genetically diverse yeast libraries, containing up to a billion distinct progeny specially engineered for industrial recombinant protein production, will be screened for cost-effective manufacture of hepatitis B, human papilloma virus and phage VLPs. Industrial technology proven to be safe for first-generation vaccine manufacture will be combined with ultra-high-throughput screening and advanced genomics to develop improved production strains for LMICs.
Impact Phenotypeca has won a Royal Society Short Industry Fellowship with Tobias von der Haar at the University of Kent, which will investigate codon optimisation of the VLP variants chosen (HPV and AP205). Phenotypeca awarded DTP CASE studentship (starting in Oct 21) with Professor Simon Avery at the University of Nottingham, for which VLP expression decrease over time in continuous fermentation is likely to be a study area.
Start Year 2020
 
Description Improvment of a Microbial Platform for Dengue Vaccine Production for Low and Medium Income Countries (LMICs) 
Organisation PT Bio Farma
Country Indonesia 
Sector Private 
PI Contribution The platform being developed uses yeast Pichia pastoris, a versatile and potentially cost-effective factory for the production of Virus-Like-Particles (VLP) for four dengue virus serotypes as a vaccine candidate. We are investigating the upstream design space to optimize both quantity and quality of the dengue vaccine prototypes (DENV1-4 vaccine). We will focus our presentation on reporting the optimisation of the upstream processing design space for the production of the serotypes, also we will report on both the quantity and the quality of the desired product, before purification steps. Furthermore, we will share our experience on how international industrial-academic partnership can successfully develop tools and technologies to de-risk scale-up and enable rapid response. So far the main achievements are: 1-Benchmark carried out in situ at Bio Farma 2-Identified-uncertainty regarding the location of VLP (intracellular vs secreted) 3-Improvment of analytics for the biophysical and biochemical properties of the product
Collaborator Contribution PT Bio Farma has hosted me at their site in Indonesia, guided me through a run through of their production process, enabling a full understanding of the entire process (UPS and DSP). During that period, I was also able to benchmark the process. Moreover, they have subsequently sent a pellet of harvested cells from their bioreactor, allowing me to begin troubleshooting and optimizing the vital quality control assays. We anticipate receipt of the stabilized producer cell-line within the next few months, at which point we will begin the process benchmarking and optimization.
Impact The expecting outputs/outcomes will be: 1- Optimization of fermentation operation Optimization of culture medium Optimization of feeding rate and induction regime Integration with initial recovery steps 2- Development of robust analytics for product characterization and quality evaluation at small scale: Biophysical properties: DLS and TEM Biochemical properties: SDS-PAGE, Western Blot, LC MS/MS Immunochemical properties: ELISA (standard and/or Luminex)
Start Year 2019
 
Description Instituto Butantan Vax-Hub Partner 
Organisation Butantan Institute
Country Brazil 
Sector Public 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description Mass spec characterisation of Virus Particle 
Organisation University of Kansas
Department Department of Pharmaceutical Chemistry
Country United States 
Sector Academic/University 
PI Contribution UCL produce and purify human adenovirus (Ad5) and run HPLC analysis on different samples (received from oxford)
Collaborator Contribution Oxford has produced and purify ChAdOx1- GFP adenovirus and prep VP (full and VP empty). Kansas is run LC/MS on all samples from UCL and oxford.
Impact 1-Establish mass spec characterization of Virus Particle 2-Use Mass Spec analysis to characterize VP maturation process to identify quality attribute 3-Implement process changes to improve VP maturation
Start Year 2020
 
Description Mass spec characterisation of Virus Particle 
Organisation University of Oxford
Department Jenner Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution UCL produce and purify human adenovirus (Ad5) and run HPLC analysis on different samples (received from oxford)
Collaborator Contribution Oxford has produced and purify ChAdOx1- GFP adenovirus and prep VP (full and VP empty). Kansas is run LC/MS on all samples from UCL and oxford.
Impact 1-Establish mass spec characterization of Virus Particle 2-Use Mass Spec analysis to characterize VP maturation process to identify quality attribute 3-Implement process changes to improve VP maturation
Start Year 2020
 
Description Merck MSD 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution Collaboration on vaccine development
Collaborator Contribution Intellectual contribution and vaccine development and production
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Merck Vax-Hub Partner 
Organisation Merck
Department Merck Sharp and Dohme Ltd
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Dissemination using database of bioscience companies / Access to proprietary roadmap for software / Sponsorship of networking events, valued @£30000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description MiniTEM analysis characterisation of VLP, viral vaccines and vectors 
Organisation Vironova
Country Sweden 
Sector Private 
PI Contribution The project will compare images obtained with the standard uracyl acetate based negative stain with those obtained using non-radiactive stains which are more suitable for use within a manufacturing QC environment. Furthermore, it will assess the suitability of MiniTEM system to provide image data of various VLPs and viral vectors to allow for setting of appropriate QC standards. The ability of the Vironova AB automated VIAS analysis software to detect variations from these defined standards as part of a QC environment will be assessed.
Collaborator Contribution Vironova AB will make available a MiniTEM system, a smaller, more compact and simpler version of the powerful analytical tool TEM, based in the Crick Institute (London) for a period of 6 months, where the team at UCL (Stephen Morris and Salome de Sa Magalhaes) will have access to. Moreover, it will provide a glow discharge to be installed at UCL BE facilities for sample preparation as well as initial training, support, sample optimisation and an expert in image analysis to extract data from the images.
Impact Successful voucher application for the period of 6 months starting in April 2020 with an allocated award value of £10K.
Start Year 2020
 
Description Optimisation of Upstream and downstream Processing for Recombinant COVID-19 expressed in Pichia pastoris 
Organisation PT Bio Farma
Country Indonesia 
Sector Private 
PI Contribution Development of fermentation and downstream processing of SARS-CoV-2 spike recombinant antigen. The goals that we want to achieve in this project are: 1) to train Bio Farma personnel on optimisation of fermentation and downstream processing for yeast-based recombinant protein 2) Tech transfer to the partner company.
Collaborator Contribution Bio Farma is responsible for sending clones and two staffs to UCL to discuss the experiment plan and get the training on optimisation of fermentation and downstream processing for yeast-based recombinant protein. Bio Farma will bear for living allowance of the staffs during the visit. The material is clone of P. pastoris expressing SARS-CoV-2 Spike protein antigen. For some experiments that are done at Bio Farma, the company will allocate personnel, instruments and materials to perform the experiments. Bio Farma will conduct study of preclinical trial in mouse model and facility to do the preclinical trial.
Impact The outcomes from this project is to give significant inputs to the acceleration of the vaccine development program in Indonesia. Bio Farma as the only human vaccine manufacturer in Indonesia, is responsible for manufacturing of the SARS-CoV-2 vaccine in the future. Thus, the optimisation study results, and the staff's training would be tremendously advantageous for Bio Farma.
Start Year 2020
 
Description PT Bio Farma Vax-Hub Partner 
Organisation PT Bio Farma
Country Indonesia 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub including valuable LMIC perspective via participation in Hub meetings,
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Pall Europe Ltd Vax-Hub Partner 
Organisation PALL Europe
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa. Other contributions e.g. provision of training and support / Dissemination using database of bioscience companies / Access to proprietary roadmap for software / Sponsorship of networking events valued @£5,000 per year.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Phenotypeca Vax-Hub Partner 
Organisation Phenotypeca
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Proof of principle synthesis of polio virus-like particles in an E. coli cell free manufacturing platform 
Organisation Univercells Ltd
Country Belgium 
Sector Private 
PI Contribution Univercells develop novel manufacturing approaches to meet global health demands in the areas of both therapeutic proteins and vaccines. Their vision of modular manufacturing to enable distributed supply of these products would be further enabled by the use of cell free synthesis. They therefore wish to investigate Leeds are world-leading experts in poliovirus and approaches to novel vaccines. Univercells will provide: 1. Design specifications for a cell free vaccine-manufacturing platform. 2. Expert advice on integration with a downstream processing. Leeds University will provide: 1. Sequences details of PV serotype of interest. 2. Anti-PV sera and control material (e.g. material expressed in yeast and/or inactivated virus) that will be used for western blotting analysis. 3. ELISA with N/C specific antibodies to detect native antigenicity following the NIBSC protocol for vaccine testing. UCL will: 1. Perform molecular design of PV VLPs/construct engineering/expression tests: 1.1. Codon-optimised sequences in encoding the P1 protein of one of the serotypes of PV (likely PV-1) and related generic 3CD protease precursor will be synthesised (Genescript services) and cloned into appropriate vectors. 1.2. Expression of the P1 polypeptide and the 3CD protease will be screened using the UCL E. coli process development platform for expression strains and a screen for optimal expression conditions will be performed. 2. Screening of E. coli-based cell free system conditions. 2.1. Cell extract prep./cell free reaction/screen for optimal conditions. 2.2. Examination of plasmid ratios between P1 polypeptide and the 3CD protease. 3. Analysis of VLP synthesis and assembly. 3.1. Production of PV capsid proteins and 3CD protease from E. coli-based cell free system will be tested by western blot using anti-PV antibodies. 3.2. The presence of assembled PV VLPs in the cell free system will be assessed using negative staining electron microscopy (EM) following clean-up using ammonium sulphate precipitation.
Collaborator Contribution Univercells delivers novel biomanufacturing platforms and solutions aimed at making biologics available and affordable to all. The Belgian company founded in 2013, is committed to acting on technology to deliver essential biologics at low costs, thereby promoting their dissemination in currently undersupplied regions. They recently introduced a NevoLine biomanufacturing platform capable of delivering large quantities of vaccines at a fraction of the traditional cost. With the support of the European Investment Bank (EIB), the company will leverage the technology to pursue its mission and make four global health vaccines more available and affordable to all. Following this success, the company is seeking to explore disruptive technologies for application in vaccine manufacturing. Cell free synthesis seems particularly appealing due to its potential to separate the fermentation / cell culture to create the cell free reaction components from the cell reaction and product synthesis step. This makes the concept of distributed / local vaccine manufacturing based more accessible. Univercells will share their expertise in understanding regulatory and technical barriers in creating modular manufacturing facilities. Our collaborators at Leeds University who lead an international WHO-funded consortium on the vaccine will share analytical materials and methods for the polio VLP components and sequence information.
Impact The collaboration it still in progress.
Start Year 2020
 
Description Sartorius Stedim Vax-Hub Partner 
Organisation Sartorius
Department Sartorius Stedim Biotech
Country France 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued at £1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Scaling and Screening Platform for PGCT Technology 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution At UCL we have developed and are working on the scaling of the current bench scale process of bioconjugation within E.coli. We are developing an automated screening platform at the microscale to screen for favourable cell culture conditions before scaling up to larger scales using engineering correlations.
Collaborator Contribution LSHTM is working on biothechnological developments of Protein Glycan Coupling Technology (PGCT) used to produce glycoconjugate vaccines in E. coli cells. The main research activities involve genetic engineering of bacterial strains, and rational design, molecular cloning, and mutagenesis of carrier proteins and glycan components of the glycoconjugate vaccines in development. Functionality of the engineered strains and vaccine production are tested at LSHTM. Selected PGCT strains are then shared with UCL for use in the automated screening platform. Both partners are working to improve and potentially optimise whole process flowsheet development aimed at minimising the steps required for glycoconjugate vaccine production in order to reduce manufacturing costs.
Impact This collaboration is multidisciplinary involving at its core two post-doctoral research fellows; from LSHTM, Marta Mauri, who specialises in the field of molecular biology ad bacteriology; and from UCL, Jasmin Samaras, who has experience in fluid mechanics and biochemical engineering. Outputs will include: -min. two publications of the work being done -a scale down automated platform for the screening of both upstream and downstream processing steps -a method to scale both to smaller and larger volumes
Start Year 2019
 
Description Serum Institute of India 
Organisation Serum Institute of India
Country India 
Sector Private 
PI Contribution We are working with SII staff to understand the reasons why some recombinant yeast isolates produce a higher yield of virus like particle vaccines than others.
Collaborator Contribution SII are providing us with genomic DNA from recombinant yeast as well as advice on optimisation of vlp yield.
Impact The work is still at an early stage with no outputs as yet.
Start Year 2019
 
Description Teesside University Vax-Hub Partner 
Organisation Teesside University
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description UK Bioindustry Association (BIA) Vax-Hub Partner 
Organisation BioIndustry Association
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including rovision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Univercells Vax-Hub Partner 
Organisation Univercells Ltd
Country Belgium 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description University of Surrey Vax-Hub Partner 
Organisation University of Surrey
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description VABiOTECH Vax-Hub Partner 
Organisation Vietnam Ministry of Health
Department Company for Vaccine and Biological Production No.1
Country Viet Nam 
Sector Public 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Provision of advice and guidance on the overall direction and progress of the Hub including valuable LMIC perspective via participation in Hub meetings, valued @£1000 per day.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Vabiotech vaccine production 
Organisation VabioTech
Country Viet Nam 
Sector Public 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production.
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Vaccitech Vax-Hub Partner 
Organisation Vaccitech Ltd
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Validation of the MiniTEM system as an analytical quality control tool for vaccine and viral vector manufacturing. 
Organisation National Physical Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution During the feasibility study the validated TEM method will be applied to a case study. We will analyse vaccine samples at different stages of the manufacturing process in collaboration with UCL and PT Bio Farma (LMIC; VLP for dengue fever) . The case study will determine and assess the performance of the validation method and determine success in addressing the challenges faced during upstream and downstream processing with direct feedback available to an LMIC partner.
Collaborator Contribution Vironova will supply the MiniTEM equipment and training of users. NPL will provide reference material
Impact The outcome will be a validated TEM analytical method with defined acceptance criteria for analysis of VLPs and viral vectors in combination with the low startup costs of the MiniTEM system will provide LMICs and the industry as whole, with valuable insight into product status throughout the manufacturing process. With almost real-time feedback at-line and significantly shorter turnaround times for data collection and interpretation compared to outsourcing TEM services, the validated method and approach will offer a cost-effective solution to accelerate vaccine development and manufacturing processes and allow rapid and informed decisions to be made in response to evolving endemic and epidemic situations.
Start Year 2020
 
Description Validation of the MiniTEM system as an analytical quality control tool for vaccine and viral vector manufacturing. 
Organisation Vironova
Country Sweden 
Sector Private 
PI Contribution During the feasibility study the validated TEM method will be applied to a case study. We will analyse vaccine samples at different stages of the manufacturing process in collaboration with UCL and PT Bio Farma (LMIC; VLP for dengue fever) . The case study will determine and assess the performance of the validation method and determine success in addressing the challenges faced during upstream and downstream processing with direct feedback available to an LMIC partner.
Collaborator Contribution Vironova will supply the MiniTEM equipment and training of users. NPL will provide reference material
Impact The outcome will be a validated TEM analytical method with defined acceptance criteria for analysis of VLPs and viral vectors in combination with the low startup costs of the MiniTEM system will provide LMICs and the industry as whole, with valuable insight into product status throughout the manufacturing process. With almost real-time feedback at-line and significantly shorter turnaround times for data collection and interpretation compared to outsourcing TEM services, the validated method and approach will offer a cost-effective solution to accelerate vaccine development and manufacturing processes and allow rapid and informed decisions to be made in response to evolving endemic and epidemic situations.
Start Year 2020
 
Description Vironova Vax-Hub Partner 
Organisation Vinnova
Country Sweden 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub (Vax-Hub)
Collaborator Contribution use of facilities/equipment e.g. access to manufacturing equipment for validating scale down studies, new and novel technologies and relevant analytical equipment/ Access to QA / Planning data / Database for network building / Analytical equipment / Manufacturing platforms Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description huvepharma 
Organisation Huvepharma
Country Bulgaria 
Sector Private 
PI Contribution Intellectual contribution, vaccine development and production.
Collaborator Contribution Intellectual contribution, vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Title ChAdOx1 nCoV-19/AZD1222 
Description ChAdOx1 nCoV-19, initially supported by VaxHUb, has been in clinical trials in UK, SA, Brazil, Kenya, US, licensed in 60 countries for emergency use 
Type Therapeutic Intervention - Vaccines
Current Stage Of Development Wide-scale adoption
Year Development Stage Completed 2020
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Demonstrated unprecedented speed of platform response. 
URL https://www.isrctn.com/ISRCTN15281137?q=ChAdOx1%20nCoV-19&filters=&sort=&offset=5&totalResults=5&pag...
 
Title Oxford/AstraZeneca COVID-19 vaccine 
Description Awards to the Douglas group enabled the manufacturing of the Oxford/AstraZeneca vaccine to take place for use in later stage clinical trials. 
Type Therapeutic Intervention - Vaccines
Current Stage Of Development Market authorisation
Year Development Stage Completed 2021
Development Status Under active development/distribution
Clinical Trial? Yes
Impact The impact of the Oxford/AstraZeneca COVID-19 have been well documented and are internationally significant. Awards to the Douglas group enabled the development of the manufacturing process required for later stage clinical trials, and global supply of the vaccine. 
 
Company Name ARKVAX LIMITED 
Description A new spin out company that derived from ArcVax was formed on 20/10/2020. The company won a competitive accelerator award and currently has labs at Babraham Research Park, Cambs and focuses on using novel glycoengineering technology for the development of glycoconjugate vaccines with a particular emphasis on animal vaccines 
Year Established 2020 
Impact The focus of the company is the development of multicomponent poultry, pig and ruminant vaccines. The business is supported contract research for vaccine candidate from established vet vaccine companies and further funding is currently being sought from a range of investors.
 
Description Radio: BBC Radio 4, The World This Weekend 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Sarah Gilbert, Professor of Vaccinology, and Tao Dong, Professor of Immunology, are interviewed about their work on a coronavirus vaccine at their lab at Oxford University. 'The stage we're at the moment is just starting to test the vaccine for immune responses in a mouse,' says Professor Gilbert. 'We're hoping to get to the first clinical trials [in humans] in June this year, and in parallel with that, we would start accelerating the large-scale manufacturing to get to the millions of doses we need. We might be at that stage by the end of the year.'
Year(s) Of Engagement Activity 2020
URL https://www.bbc.co.uk/sounds/play/m000fygq
 
Description Run, don't walk: Scientists are racing to produce a vaccine for the latest coronavirus The Economist, 05/02/2020 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Sarah Gilbert of Oxford's Nuffield Department of Medicine comments on the process of vaccine development.
Year(s) Of Engagement Activity 2020
URL https://www.economist.com/international/2020/02/05/the-race-to-produce-a-vaccine-for-the-latest-coro...
 
Description Two British scientists in race to develop coronavirus vaccine, Evening Standard, 07/02/2020, p.5, Ross Lydall 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Article states two British scientists Robin Shattock of Imperial College and Oxford's Professor Sarah Gilbert are racing to find a vaccine for the coronavirus.
Year(s) Of Engagement Activity 2020
URL https://eveningstandard.podbean.com/e/two-groups-of-british-scientists-in-race-to-develop-coronaviru...
 
Description 30+ TV interviews (BBC, SKY, Channel 4) on Covid vaccine delivery, production and use 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact 30+ TV interviews (BBC, SKY, Channel 4) on Covid vaccine delivery, production and use.
Received 100s of questions from general public many relating to vaccine confidence
Year(s) Of Engagement Activity 2020
 
Description 5 international TV interviews (eg BBC News, Swiss and Russian TV) on Covid vaccine delivery, production and use as well as SARS2-CoV epidemiology 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact 5 international TV interviews (eg BBC News, Swiss and Russian TV) on Covid vaccine delivery, production and use.
Received dozens of questions from general public many relating to vaccine confidence
Year(s) Of Engagement Activity 2020
 
Description 5 invited newspaper articles in Daily Mail TV interviews on Covid vaccine delivery, production and use. 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact 5 invited newspaper articles in Daily Mail TV interviews on Covid vaccine delivery, production and use.
Numerous response from general public who have felt reassured about taking Covid vaccine.
Year(s) Of Engagement Activity 2020
 
Description Andrew Marr via BBC 7Feb2021 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Impact unknown but reached a large audience.
Year(s) Of Engagement Activity 2021
URL https://www.bbc.co.uk/programmes/p09699wz
 
Description Article in The Conversation: Coronavirus: how the pharma industry is changing to produce a vaccine on time. By Stephen Morris and Beatrice Melinek 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Article in The Conversation a general interest science on-line magazine titled: "Coronavirus: how the pharma industry is changing to produce a vaccine on time". By Stephen Morris and Beatrice Melinek. Generated feed back in form of direct request for information a and potential collaboration.
Year(s) Of Engagement Activity 2020
URL https://theconversation.com/coronavirus-how-the-pharma-industry-is-changing-to-produce-a-vaccine-on-...
 
Description BBC Panorama Oxford COVID vaccine documentary 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact The inside story of the development of the Oxford vaccine against Covid-19. Fergus Walsh scrutinises the data that has come out of the trials, and examines the vaccination's efficacy and safety.
Year(s) Of Engagement Activity 2020
URL https://www.bbc.co.uk/iplayer/episode/m000qdzd/panorama-the-race-for-a-vaccine
 
Description BBC Radio Oxford, Adam and Michelle, 08/02/20, 06:00 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Comment from Professor of Vaccinology Sarah Gilbert on health workers being particularly at risk from coronavirus.
Year(s) Of Engagement Activity 2020
URL https://www.bbc.co.uk/programmes/p0815vgg
 
Description Britons on Sunday evacuation flight from coronavirus-hit Wuhan will be held in Milton Keynes, Mail Online UK, 07/02/2020 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Leading virologists and infectious disease specialists met at a hastily organised meeting by the respected Science Media Centre in London today amid the escalating outbreak. The panel of six included Dr Gail Carson, Consultant in Infectious Diseases, University of Oxford and Sarah Gilbert, Professor of Vaccinology, University of Oxford.
Year(s) Of Engagement Activity 2020
URL https://www.dailymail.co.uk/health/article-7979963/Britons-Sunday-evacuation-flight-coronavirus-hit-...
 
Description COVID-19 vaccine manufacturing press engagment 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Alexander Douglas and Adam Ritchie have both been engaged with the media on the Oxford/AstraZeneca vaccine manufacturing process. This includes:

-Appearance on Panarama (BBC, UK)
-Quotes/interviews in numerous newspaper and maganzine articles (UK focused)
-Radio interviews (including BBC radio 5 (UK) and World Service (international))
Year(s) Of Engagement Activity 2020,2021
 
Description Coronavirus crisis: Expert warns that vaccine will take at least a year to develop Daily Express, 25/01/2020 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Professor Sarah Gilbert, an expert on malaria vaccination from Oxford University, comments on the timescales for developing a vaccine for the coronavirus: "It is still going to take us several months before we have a vaccine that is ready to go into the first clinical trials."
Year(s) Of Engagement Activity 2020
 
Description Economist interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact I was interviewed by a journalist from The Economist
Year(s) Of Engagement Activity 2020
URL https://www.economist.com/international/2020/02/06/the-race-to-produce-a-vaccine-for-the-latest-coro...
 
Description Global health alert as mystery virus triggers Sars-type pneumonia outbreak in China The Daily Telegraph Online, 09/01/2020 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Sarah Gilbert, professor of vaccinology at the Jenner Institute at Oxford University, comments on the emergence of a new coronavirus that has been identified in China.
Year(s) Of Engagement Activity 2020
URL https://www.telegraph.co.uk/global-health/science-and-disease/chinas-pneumonia-outbreak-caused-myste...
 
Description Human trials of £27bn virus vaccine to start next month The Daily Telegraph, 04/03/2020, p.4, Sarah Knapton 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Coverage of Professor Sarah Gilbert's research group at the University of Oxford's Nuffield Department of Medicine, which is working on a coronavirus vaccine using the same technology they used to generate a prototype inoculation for the 2012 Middle East Respiratory Syndrome (Mers) outbreak.
Year(s) Of Engagement Activity 2020
URL https://www.telegraph.co.uk/science/2020/03/03/will-have-coronavirus-vaccine-human-trials-begin-apri...
 
Description Invited Talk at The Institutions of Engineering and Technology Central London Network, title "When Engineering Meets Biology" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Invited presentation at an IET Central London Network event held at IET Savoy Place to an audience of engineers and members of the general public of approximately 60 people. Presentation featured advances in synthetic biology utilised by the industry to create promising new technologies and explore how these can help to solve pressing needs in global health such as vaccine development.
Year(s) Of Engagement Activity 2020
URL https://communities.theiet.org/groups/blogpost/view/197/121/6828
 
Description MBI Rapid Fermentation Process Design 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Workshop on design and specification of bioreactors and the application of microscale techniques for rapid fermentation process development and scale-up. Course objectives were the following:
- Understand engineering principles of fermentation.
- Determine power consumption and oxygen mass transfer.
- Evaluate different strategies for scale-up and scale-down.
- Know about miniaturised bioreactors and their role in fermentation process development.
- Understand how to design a bioreactor and use data from microscale experiments for scaleup.

Gained basic theoretical knowledge of fermentations in bioreactors.
Year(s) Of Engagement Activity 2019
URL https://www.ucl.ac.uk/biochemical-engineering/research/mbi/courses/rfpd
 
Description MBI Vaccine Bioprocess Development and Commercialisation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact I attended this 4-days training course/workshop delivered by UCL members (including Vax-Hub members) in collaboration with the Massachusetts Institute of Technology (MIT).
This MBI helped scientists, postgraduate students, process engineers and policy makers to further their knowledge on the challenges associated to vaccine processes and commercialisation.
Year(s) Of Engagement Activity 2021
 
Description MBI Vaccine Bioprocess Development and Commercialization 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Workshop exploring critical issues at the various stages of vaccine development. International experts with over 10 years' experience in their field lead delegates in developing their understanding in the research, development, operational and regulatory challenges of the vaccine market.
Expanded knowhow and relevant network in vaccinology.
Year(s) Of Engagement Activity 2021
URL https://www.ucl.ac.uk/biochemical-engineering/research/mbi/courses/VBDC
 
Description May 2019 and November 2019 Vax-Hub Users Group Meetings 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact These all-day events bring together Vax-Hub researchers and academics and current and prospective industry collaborators. The events feature research updates, industry presentations, a poster session and networking. The purpose of the events is to share knowledge and build new and existing collaborative relationships between industry and academia. As a result, some of those present have since formed collaborations and joined the Hub.
Year(s) Of Engagement Activity 2019
 
Description On-line Q&A session dicussing Vaccines and Gene Therapy with pupils from Edron Academy, Mexico 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact At the end of September Dr Rana Khalife and Dr Stephen Morris joined UCL Biochemical Engineering Alumnus Balasundaram Bangaru for an online talk with his pupils at the Edron Academy. They discussed research, engineering and especially Stem Cell and Gene Therapy and Vaccines. Generated interesting feedback from students and school staff.
Year(s) Of Engagement Activity 2020
URL https://www.ucl.ac.uk/biochemical-engineering/news/2020/oct/researchers-give-talk-school-pupils-mexi...
 
Description Opinion paper (The Engineer) - Scaling up UK vaccine manufacture 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact An opinion article in The Engineering on the challenges of scaling up vaccine manufacturing, prepared in collaboration with our colleagues from the Vaccine Manufacturing Research Hub led by Imperial College.
Year(s) Of Engagement Activity 2020
URL https://www.theengineer.co.uk/scaling-up-uk-vaccine-manufacture
 
Description Policy brief on biomanufacturing 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Policy brief published on the UK biomanufacturing industry highlighting the Hub's expertise in this area and strategic fit within a national investment portfolio
Year(s) Of Engagement Activity 2020
URL https://www.ucl.ac.uk/steapp/sites/steapp/files/biomanufacturing_briefing_jan_2020.pdf
 
Description Policy brief on vaccine development during a pandemic 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact In part one of two briefings we look at how vaccines work, how new vaccines are discovered and how this is being accelerated to meet the urgent need for distribution of an effective vaccine against the SARS-CoV-2 virus worldwide.
Year(s) Of Engagement Activity 2020
URL https://www.ucl.ac.uk/steapp/collaborate/policy-impact-unit/policy-brief-developing-new-vaccines-pan...
 
Description Policy brief on vaccine manufacturing during a pandemic 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact In part two of two briefings we look at how different platform vaccines are manufactured and how adopting flexible manufacturing approaches is likely to have biggest impact on slowing the COVID-19 pandemic, enabling doses of the COVID-19 vaccine to be delivered most rapidly. Technologies to increase manufacturing capacity in low and middle income countries are explored.
Year(s) Of Engagement Activity 2020
URL https://www.ucl.ac.uk/steapp/collaborate/policy-impact-unit/policy-brief-manufacturing-new-vaccines-...
 
Description Poster presentation at 7th analytical biosciences early career researcher meeting (Glasgow) - 'molecular design & production of high-quality foot-and-mouth disease virus (FMDV) virus-like particles VLPs 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Poster presentation at the at 7th analytical biosciences early career researcher meeting (March 2020, Glasgow), see below the abstract:
'The foot-and-mouth disease virus (FMDV) is a highly-contagious disease of cloven-hoofed animals whose etiological agent is the foot-and-mouth disease virus (FMDV), an aphthovirus member of the Picornaviridae family. The FMD remains endemic in many countries around the world where it has severe impacts on livestock trade and food production. Current commercial FMD vaccines consist of chemically inactivated FMDV whose production requires large cultures of live virus and a cold storage chain, which involves numerous risks and limitations. Therefore, safer and cost effective vaccines such as virus-like particles (VLPs) can be a valuable alternative to control the FMD.
This work seeks to produce high-quality FMD-VLPs and explore suitable analytics to improve FMD VLPs quality, yield and stability.
So far, structural and biochemical information of the FMDV have been used for the molecular design of FMD VLPs and a small library of recombinant vectors encoding structural components of the FMDV is now available. Optimal conditions for the expression of FMD-VLPs in E. coli have been found and first attempts of large-scale protein purification using a combination of chromatography techniques followed by western blot analysis and negative-stain electron microscopy, showed that FMD-VLPs can be produced.
Year(s) Of Engagement Activity 2020
 
Description Presentation by Jasmin Samaras as part of 2020 bioprocessing webinar series from Tecan and Valitacell: An integrated microscale platform for the automated screening of a novel glycoconjugate vaccine expression system 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation titled "An integrated microscale platform for the automated screening of a novel glycoconjugate vaccine expression system". As part of industry sponsored technical webinar series. Generated feedback and request for information and potential collaboration.
Year(s) Of Engagement Activity 2020
URL https://www.tecan.com/free-webinar-series-bioprocessing
 
Description Presentation by Stephen Morris as part of 2020 bioprocessing webinar series from Tecan and Valitacell: Use of high throughput methodologies in the holistic process development of a subunit rotavirus vaccine candidate produced in Pichia pastoris 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation titled "Use of high throughput methodologies in the holistic process development of a subunit rotavirus vaccine candidate produced in Pichia pastoris". As part of industry sponsored technical webinar series. Generated feedback and request for information and potential collaboration.
Year(s) Of Engagement Activity 2020
URL https://www.tecan.com/free-webinar-series-bioprocessing
 
Description Radio: BBC Radio Oxford, Sophie Law. 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Coverage of a second student testing positive for coronavirus and continuing efforts to find a vaccine at Oxford University. Professor Sarah Gilbert from the Jenner Institute provides a timeline on how a vaccine could roll out over coming months.
Year(s) Of Engagement Activity 2020
URL https://www.bbc.co.uk/programmes/p0837w6v
 
Description Radio: LBC 97.3, Eddie Mair 22/01/2020 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Professor of Vaccinology, Sarah Gilbert, explains what the coronavirus is and how it progresses.
Year(s) Of Engagement Activity 2020
 
Description Small firms, big prize: the Covid-19 vaccine race The Sunday Telegraph, 08/03/20, p.8, Hannah Uttley 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Article on scientists working on a coronavirus vaccine highlights a group run by Prof Sarah Gilbert at Oxford University's Nuffield Department of Medicine. It uses the same technology they used to generate a prototype inoculation for the 2012 Middle East respiratory syndrome (Mers) outbreak. The university has agreed a contract with drug discovery research firm IRBM's Italian manufacturer Advent Srl to produce the first batch of a novel coronavirus vaccine for clinical testing. The vaccine "seed stock" has been produced at the university's clinical biomanufacturing facility, and transferred to Advent, which will initially produce 1,000 doses for the first clinical trials of the vaccine.
Year(s) Of Engagement Activity 2020
 
Description Stephen Morris Interviewed for The Guardian Science Weekly PodCast series: Covid-19: How do you make a vaccine? 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Interview on the process and challenges of vaccine manufacture in relation to COVID 19 epidemic. Intended for a general interested public audience. Generated followup media interest, with request for further information.
Year(s) Of Engagement Activity 2020
URL https://www.theguardian.com/science/audio/2020/nov/03/covid-19-how-do-you-make-a-vaccine-podcast
 
Description Stephen Morris interviewed for contribution to Huffpost article: This Is The UK's Path Out Of Covid Hell - And How Long It Will Take. 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Interviewed and quoted for the article "This Is The UK's Path Out Of Covid Hell - And How Long It Will Take" . in the Huffpost. Generated further media requests for information.
Year(s) Of Engagement Activity 2020
URL https://www.huffingtonpost.co.uk/entry/path-out-of-coronavirus-pandemic_uk_5fec8b4bc5b64e4421081fff?...
 
Description Training course - MBI Vaccine Bioprocess Development and Commercialisation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The MBI Vaccine Bioprocess Development and Commercialisation is a training course delivered by UCL in collaboration with Massachusetts Institute of Technology (MIT). The course assists in developing knowledge on the challenges of creating vaccine processes and offers intensive training over 3-4 days for research scientists, programme managers, process engineers and policy makers. The course is taught by experts in the field from industry and academia and is accessible to those new to vaccine development or those working in the field. 66 international delegates from academia and industry attended the online course 2021. The course has received Bill & Melinda Gates Funding which has sponsored attendance of 20 LMIC delegates since 2019, for example from Vietnam, Thailand, Brazil, India and Indonesia. As part of the 2021 delivery, various Vax-Hub members co-organised a Workshop: "Strategies for commercial specifications for vaccines - product quality requirements and process analytics" that sparked discussions amongst the delegates on the topic of vaccine analytics.
Year(s) Of Engagement Activity 2019,2021
URL https://www.ucl.ac.uk/biochemical-engineering/research/mbi/courses/VBDC
 
Description Training course - MBI Vaccine Bioprocess Development and Commercialisation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The MBI Vaccine Bioprocess Development and Commercialisation is a training course delivered by UCL in collaboration with Massachusetts Institute of Technology (MIT). The course assists in developing knowledge on the challenges of creating vaccine processes and offers intensive training over 3-4 days for research scientists, programme managers, process engineers and policy makers. The workshop mainly was focused on adenoviral vaccines production and the analytical tools needed for best quality controls.
Year(s) Of Engagement Activity 2021
 
Description Vaccine Bioprocess Development and Commericialisation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Delivered in collaboration with Massachusetts Institute of Technology (MIT), this course will assist in developing your knowledge on the challenges of creating a vaccine process.

This course will explore the critical issues at the various stages of vaccine development. International experts with over 10 years' experience in their field will lead delegates in developing their understanding in the research, development, operational and regulatory challenges of the vaccine market. In addition to expert lectures and excellent networking opportunities with your peers, one case study will be conducted during the workshop about manufacturing at-risk with real examples from the influenza manufacturing process.

Topics covered will include:
• Scale-up from lab to pilot scale.
• Quality by Design (QbD) as part of vaccine development.
• Expression systems.
• Single use platforms.
• Regulation and its impact on development.
• Final formulation and adjuvants.
• Developing world needs.
Year(s) Of Engagement Activity 2021
URL https://www.ucl.ac.uk/biochemical-engineering/research/mbi/courses/VBDC
 
Description Vax-Hub & CPI Process Development Webinar - mRNA Vaccine Manufacture 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The EPSRC Vax-Hub based at UCL Biochemical Engineering organised a webinar in October 2020, in collaboration with the Centre of Process Innovation (CPI) on the challenges associated with manufacturing an mRNA vaccine with a focus on the self-amplifying RNA (saRNA) format, featuring Dr Andrew Tait (UCL Biochemical Engineering, host) and Dr John Liddell (CPI Biologics Chief Technologist, speaker).
Year(s) Of Engagement Activity 2020
URL https://youtu.be/95zEcfmQ_6Y
 
Description Vax-Hub & MSD Process Development Webinar - Intelligent Automation of High Throughput Chromatography 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The EPSRC Vax-Hub based at UCL Biochemical Engineering organised a webinar in October 2020, in collaboration with MSD on "Intelligent Automation of High Throughput Chromatography for Enabling Wide Adoption of HTPD Workflows in Vaccines Process Development", featuring Dr Salome de Sa Magalhaes (Vax-Hub Research Fellow, host) and Dr Spyridon Konstantinidis (MSD Senior Scientist, speaker).
Year(s) Of Engagement Activity 2020
URL https://youtu.be/t81mzhOXT_4
 
Description Vax-Hub & Malvern Panalytical Analytics Webinar - DLS & NTA Techniques to Characterise VLPs 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The EPSRC Vax-Hub based at UCL Biochemical Engineering organised a webinar in June 2020, in collaboration with Malvern Panalytical on the use of Dynamic Light Scattering (DLS) and Nanotracking (NTA) techniques to characterise Virus-Like Particles (VLPs), featuring Dr. Stephen Morris (Vax-Hub Research Fellow, host), and Dr. Michael Kaszuba (Malvern Technical Support Manager) and Ms. Agnieszka Supa (Malvern Product Manager Nano-Materials).
Year(s) Of Engagement Activity 2020
URL https://youtu.be/K4a6JbkApQw
 
Description Vax-Hub & VAFC Analytics Webinar - Applying Mass Spectrometry to Vaccine Development at VAFC 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The EPSRC Vax-Hub based at UCL Biochemical Engineering organised a webinar in July 2020, in collaboration with the Vaccine Analytics and Formulation Center (VAFC) at Kansas University (KU), on the mass spectrometry capabilities and VAFC case studies illustrating how this technique has identified and addressed both process- and product-related issues, featuring Dr. Stephen Morris (Vax-Hub Research Fellow, host) and Dr. John Hickey (VAFC Scientific Assistant Director, speaker).
Year(s) Of Engagement Activity 2020
URL https://youtu.be/ZL1fPM4_xQc
 
Description Vax-Hub & Vironova Analytics Webinar - MiniTEM for Biophysical Characterisation of AAV Samples 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The EPSRC Vax-Hub based at UCL Biochemical Engineering organised a webinar in June 2020, in collaboration with Vironova consisting in a full live MiniTEM imaging session and data analysis workflow for the biophysical characterisation of Adeno-Associated Virus (AAV) samples, featuring Dr. Salome de Sa Magalhaes (Vax-Hub Research Fellow, host), and Dr. Saba Hussein-Gore (Vironova Applications Manager and Senior Scientist, speaker).
Year(s) Of Engagement Activity 2020
URL https://youtu.be/na_0uiCl1Eo
 
Description Vax-Hub & Vironova Analytics Webinar - MiniTEM for Biophysical Characterisation of VLPs samples 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact The EPSRC Vax-Hub based at UCL Biochemical Engineering organised a webinar in November 2020 in collaboration with Vironova, on how the small footprint and semi-automated transmission electron microscope (TEM) system, MiniTEM, can be used to as an analytical tool for VLPs characterization and what to consider when assessing these particles, featuring Dr. Salome de Sa Magalhaes (Vax-Hub Research Fellow, host) and Dr. Adam Dickinson (Vironova Application Specialist, speaker).
Year(s) Of Engagement Activity 2020
URL https://youtu.be/Z5wmPYFDDqQ
 
Description Vax-Hub Newsletter #1 - Focus on Viral-Vectored Vaccines 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Dissemination of the latest news on Hub research, meetings, events, team and the latest publications
Year(s) Of Engagement Activity 2020
URL https://mailchi.mp/0b2b3ed513b5/vaxhub-newsletter-1
 
Description Vax-Hub Newsletter #2 - Focus on VLP-based Vaccines 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Dissemination of the latest news on Hub research, meetings, events, team and the latest publications
Year(s) Of Engagement Activity 2020
URL https://mailchi.mp/0b47c627482e/vaxhub-newsletter-2
 
Description Vax-Hub Newsletter #3 - Focus on Conjugate Vaccines 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Dissemination of the latest news on Hub research, meetings, events, team and the latest publications
Year(s) Of Engagement Activity 2020
URL https://mailchi.mp/62669b232b4c/vaxhub-newsletter3
 
Description Vax-Hub Newsletter #4 - Special Issue dedicated to Vax-Hub Feasibility Studies 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Dissemination of the latest news on Hub research, meetings, events, team and the latest publications
Year(s) Of Engagement Activity 2020
URL https://mailchi.mp/0838b64f76b7/vaxhub-newsletter4
 
Description Vax-Hub Newsletter #5 - Focus on Protein Production Platforms for Vaccine Development 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact I have provided a brief overview of the research I am carrying out within the Vax-Hub. I have provided a description of the molecular design of Foot-and-mouth virus (FMDV) and polio virus (PV) virus-like particles (VLPs) and their production using E. coli cells and E.coli-based cell-free systems.
Year(s) Of Engagement Activity 2021
 
Description Vax-Hub Newsletter #5 - Focus on Protein Production Platforms for Vaccine Development 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Dissemination of the latest news on Hub research, meetings, events, team and the latest publications
Year(s) Of Engagement Activity 2020
URL https://mailchi.mp/a27f5d29d5f4/vaxhub-newsletter5
 
Description Viral Vectors for Vaccines and Gene Delivery Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact This one-day meeting was jointly organised by the Future Vaccine Manufacturing Research Hub (Vax-Hub), the Future Targeted Healthcare Manufacturing (FTHM) Hub and the Knowledge Transfer Network and offered a programme of invited talks, a poster session and an interactive panel discussion. The meeting brought together ~110 participants from industry, academia, government, sector organisations, to inform and discuss the common manufacturing and analytical challenges across the major viral vector products.
Year(s) Of Engagement Activity 2019
 
Description magazine interview 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Dissemination of the latest news on Hub research, meetings, events, team and the latest publications
Year(s) Of Engagement Activity 2020